Cisplatin-based chemotherapy for advanced seminoma: Report of 52 cases treated in two institutions

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 11, 2009, Pages 1495-1500

  Giannis, Mountzios ^a   Aristotelis, Bamias ^b   Vassiliki, Koutsoukou ^b   Ioannis, Anastasiou ^c   Konstantinos, Stravodimos ^c   Nikolaos, Antoniou ^d   Georgios, Papadopoulos ^e   Georgios, Pavlakis ^e   Pantelis, Papassavas ^e   Meletios Athanasios, Dimopoulos ^b  

^a University Hospital Alexandra ^*  (Greece)

^b University Hospital Alexandra   (Greece)

^c Laikon University   (Greece)

^d AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^e 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Advanced seminoma; Cisplatin based chemotherapy; IGCCCG classification; Risk adapted therapy; Testicular tumors

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE; ANTINEOPLASTIC AGENT; BEP PROTOCOL;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; SALVAGE THERAPY; SEMINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; TESTIS TUMOR; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 70349565960     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0596-2     Document Type: Article

References (24)

1. Cancer Therapy Evaluation Program (2003), Common Terminology Criteria for Adverse Events v4.0 (CTCAE), March 31, 2003 ( http://ctep.cancer.gov )
2. Cullen M, Harper G, Woodroffe et al (1988) Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol 62(5):454-460. doi: 10.1111/j.1464-410X.1988.tb04396.x
3. M De Santis C Bokemeyer A Becherer, et al. 2001 Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma J Clin Oncol 19 17 3740 3744 11533096
4. R De Wit J Roberts P Wilkinson, et al. 2001 Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol 19 6 1629 1640 11250991
5. S Fossa R de Wit T Roberts, et al. 2003 Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20) J Clin Oncol 21 6 1107 1118 10.1200/JCO.2003.02.075 12637478 10.1200/JCO.2003.02.075 (Pubitemid 46594141)
6. X Garcia-del-Muro P Maroto J Guma, et al. 2008 Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study J Clin Oncol 26 5416 5421 10.1200/JCO.2007.15.9103 18936476 10.1200/JCO.2007.15.9103 1:CAS:528: DC%2BD1MXhslClsw%3D%3D
7. D Gholam K Fizazi M-J Terrier-Lacombe, et al. 2003 Advanced Seminoma-treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease Cancer 98 4 745 752 10.1002/cncr.11574 12910518 10.1002/cncr.11574 (Pubitemid 36959270)
8. M Guden C Ulutin S Goktas 2001 Analyses of 98 seminoma cases: a review article Int Urol Nephrol 33 529 531 10.1023/A:1019502326432 12230289 10.1023/A:1019502326432 1:STN:280:DC%2BD38vntVSrtg%3D%3D (Pubitemid 34936500)
9. A Horwich J Shipley R Huddart 2006 Testicular germ-cell cancer Lancet 367 754 765 10.1016/S0140-6736(06)68305-0 16517276 10.1016/S0140-6736(06)68305-0 1:CAS:528:DC%2BD28XitVejsrw%3D (Pubitemid 43326294)
10. International Germ Cell Consensus Classification (1997) a prognostic factor-based staging system for metastatic germ cell cancers. International germ Cell Consensus Group. J Clin Oncol 15:594-603
11. S Krege J Beyer R Souchon, et al. 2008 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I Eur Urol 53 3 478 496 10.1016/j.eururo.2007.12.024 18191324 10.1016/j.eururo.2007.12.024
12. PJ Loehrer R Gonin CR Nichols, et al. 1998 Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 16 2500 2504 9667270 1:CAS:528:DyaK1cXks1Gnur8%3D
13. JA McCaffrey M Mazumdar DF Bajorin, et al. 1997 Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival J Clin Oncol 15 2559 2563 9215825 1:CAS:528:DyaK2sXkslymsrY%3D
14. Mencel P, Motzer R, Mazumdar et al (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12(1):120-126
15. K Miller P Loehrer R Gonin L Einhorn 1997 Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma J Clin Oncol 15 4 1427 1431 9193335 1:CAS:528:DyaK2sXivVehsrc%3D
16. R Motzer M Mazumdar S Gulati, et al. 1993 Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors J Natl Cancer Inst 85 22 1828 1835 10.1093/jnci/85.22.1828 7693955 10.1093/jnci/85.22.1828 1:STN:280:DyaK2c%2FkslWgtg%3D%3D (Pubitemid 23333615)
17. R Motzer M Mazumdar D Bajorin G Bosl 1997 High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors J Clin Oncol 15 7 2546 2552 9215823 1:CAS:528:DyaK2sXkslymsrg%3D
18. R Motzer D Bajorin Schwartz, et al. 1994 Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors J Clin Oncol 12 11 2277 2283 7525885 1:STN:280:DyaK2M%2FlsVantQ%3D%3D
19. CR Nichols PJ Catalano ED Crawford, et al. 1998 Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Meukemia Group B study J Clin Oncol 16 1287 1293 9552027 1:CAS:528:DyaK1cXis1GhsLo%3D
20. H Puc R Heelan M Mazumdar, et al. 1996 Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center J Clin Oncol 14 2 454 460 8636757 1:STN:280:DyaK283itlCjsw%3D%3D
21. S Saxman D Finch R Gonin E Einhorn 1998 Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumours: The Indiana University experience J Clin Oncol 16 2 702 706 9469360 1:CAS:528:DyaK1cXhtFShtbc%3D
22. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10.1093/jnci/92.3.205 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
23. AW van den Belt-Dusebout R de Wit JA Gietema, et al. 2007 Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 28 4370 4378 10.1200/JCO.2006.10.5296 10.1200/JCO.2006.10.5296 (Pubitemid 350013842)
24. R de Wit G Stoter SB Kaye, et al. 1997 Importance of bleomycinin combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837 1843 9164193